Identifying Unmet Needs, Building Next-Generation Research Tools
Guided by our core brand value of "Integrated Innovation", ACROBiosystems is committed to building an open and collaborative platform that brings together cutting-edge ideas and core technologies. We strive to transform creative concepts into real-world solutions, accelerate technology transfer, support high-quality industrial development, and ultimately contribute to safeguarding human health.
As a frontier direction in cell therapy, in vivo CAR-T therapy is advancing at an extraordinary pace. However, the field continues to face significant R&D challenges, unmet experimental needs, and critical tool gaps. To help address these bottlenecks, we are proud to launch the In Vivo CAR-T Innovative Tool Co-Creation Initiative—a program focused on real-world R&D pain points. We sincerely invite academic researchers and industry partners to collaborate with us in co-creating the next generation of specialized R&D tools.




This program is designed for professionals with deep expertise in in vivo CAR development, including but not limited to:
In vivo CAR
research scientist
Pharmacology and pharmacodynamics experts
In vivo CAR process and analytical development professionals (CMC)
Technology platform leaders
Clinical researchers
We also welcome experts from adjacent fields who are actively driving innovation in in vivo cell therapy.
Targeting & Engineering
Target discovery & validation
CAR design & optimization
Delivery systems
Functional Testing
Transduction & expression analysis
In vitro functional assays
CMC Development
Process Development
Technology Transfer
QC Testing
Preclinical & Clinical Studies
Efficacy studies
Safety assessment
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



